Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer

Inclusion Criteria:

* Documented informed consent of the participant
* Age: \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) =\< 2
* Ability to read and understand English or Spanish for questionnaires
* Documented diagnosis of metastatic breast cancer with at least a 6 month life expectancy
* A planned course of taxane based chemotherapy in the metastatic setting, including paclitaxel, docetaxel or abraxane
* At least 6 months from the last chemotherapy causing hair loss with complete recovery of hair
* Willing to be contacted for brief annual assessments for five years
* Women of childbearing potential (WOCBP): negative urine pregnancy test
* Agreement by females of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study

  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

Exclusion Criteria:

* Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss
* A history of whole brain radiation with persistent hair thinning or alopecia, or concurrent whole brain radiation therapy
* Exposure to other investigational agents, drugs, device or procedure that may cause hair loss
* Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale
* Any cutaneous scalp metastases
* Clinically significant liver dysfunction considered significant as determined by treating physician that would limit the patient's ability to administer the scalp cooling device
* Clinically significant renal dysfunction considered significant as determined by treating physician that would limit the patient's ability to administer the scalp cooling device
* A history of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens
* Evidence of untreated or poorly controlled hyper or hypothyroidism
* American Society of Anesthesiologist Class \>= 3
* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
* Pregnant or breastfeeding
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)